Literature DB >> 15685652

Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis.

Andrew R Willan1, Eleanor M Pinto, Bernie J O'Brien, Padma Kaul, Ron Goeree, Larry Lynd, Paul W Armstrong.   

Abstract

The growing number of multinational clinical trials in which patient-level health care resource data are collected have raised the issue of which is the best approach for making inference for individual countries with respect to the between-treatment difference in mean cost. We describe and discuss the relative merits of three approaches. The first uses the random effects pooled estimate from all countries to estimate the difference for any particular country. The second approach estimates the difference using only the data from the specific country in question. Using empirical Bayes estimation a third approach estimates the country-specific difference using a variance-weighted linear sum of the estimates provided by the other two approaches. The approaches are illustrated and compared using the data from the ASSENT-3 trial. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15685652     DOI: 10.1002/hec.969

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  13 in total

1.  The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.

Authors:  Andrea Manca; Mark J Sculpher; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions?

Authors:  Mark J Sculpher; Michael F Drummond
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Better analysis for better decisions: has pharmacoeconomics come of age?

Authors:  Michael Drummond; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data.

Authors:  Andrea Manca; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  The generalisability of pharmacoeconomic studies: issues and challenges ahead.

Authors:  James M Mason; Anne R Mason
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.

Authors:  Andrew R Willan; Ron Goeree; Eleanor M Pullenayegum; Christopher McBurney; Gordon Blackhouse
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 7.  Assessing generalisability in model-based economic evaluation studies: a structured review in osteoporosis.

Authors:  Hege Urdahl; Andrea Manca; Mark J Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling.

Authors:  Andrea Manca; Paul C Lambert; Mark Sculpher; Nigel Rice
Journal:  Med Decis Making       Date:  2007-07-19       Impact factor: 2.583

Review 9.  The road not taken: transferability issues in multinational trials.

Authors:  Pepijn Vemer; Maureen P M H Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

10.  Multivariate Generalized Linear Mixed-Effects Models for the Analysis of Clinical Trial-Based Cost-Effectiveness Data.

Authors:  Felix Achana; Daniel Gallacher; Raymond Oppong; Sungwook Kim; Stavros Petrou; James Mason; Michael Crowther
Journal:  Med Decis Making       Date:  2021-04-05       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.